Early use of fondaparinux at therapeutic dosage in COVID-19 infection
Minerva Anestesiol
.
2021 Aug;87(8):958-960.
doi: 10.23736/S0375-9393.21.15792-X.
Epub 2021 May 7.
Authors
Battista Borghi
1
2
,
Raffaele Borghi
3
4
,
Tiziana DE Amicis
5
,
Caterina Sommariva
6
,
Gennaro Pipino
3
4
Affiliations
1
Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy - battista.borghi@unibo.it.
2
Research Unit of Anesthesia and Pain Therapy, Rizzoli Orthopedic Institute, Bologna, Italy - battista.borghi@unibo.it.
3
University Campus Malta Swiss Ludes Campus, Lugano, Switzerland.
4
Villa Regina Hospital, Garofalo Health Care, Bologna, Italy.
5
Family Doctor, Casalecchio di Reno, Bologna, Italy.
6
Home COVID Care Unit (USCA) Penne, Pescara, Italy.
PMID:
33960182
DOI:
10.23736/S0375-9393.21.15792-X
No abstract available
MeSH terms
Anticoagulants / adverse effects
COVID-19*
Factor Xa Inhibitors
Fondaparinux
Humans
SARS-CoV-2
Substances
Anticoagulants
Factor Xa Inhibitors
Fondaparinux